Carisma Therapeutics Q2 2024 net loss $11.2M; CT-0525 data expected by year-end

Carisma Therapeutics Inc.

2024-Q2 EPS reported -$0.73 revenue$12,600,000

Net loss improved to $11.2M in Q2 2024 from $19.9M in Q2 2023; R&D expenses declined to $15.3M.
Cash and equivalents $40.4M at June 30, 2024; expects to fund operations into Q3 2025.
Initial data from CT-0525 Phase 1 trial for HER2+ solid tumors expected by year-end 2024; FDA Fast Track granted.
Nominated first in vivo CAR-M development candidate targeting GPC3 under Moderna collaboration; $2.0M milestone received.
Liver fibrosis program development candidate nomination expected in Q1 2025; preclinical data at AASLD in Nov 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.